4//SEC Filing
HAMER JOHN 4
Accession 0000899243-20-034349
CIK 0001703057other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 8:35 PM ET
Size
18.1 KB
Accession
0000899243-20-034349
Insider Transaction Report
Form 4
HAMER JOHN
Director10% Owner
Transactions
- Conversion
Common Shares
2020-12-15+29,076,350→ 29,076,350 total(indirect: See footnote) - Conversion
Series A1 Preferred Shares
2020-12-15−2,105,264→ 0 total(indirect: See footnote)→ Common Shares (21,052,640 underlying) - Conversion
Common Shares
2020-12-15+29,411→ 29,105,761 total(indirect: See footnote) - Award
Convertible Note
2020-12-11$500000.00/sh(indirect: See footnote)→ Common Shares (29,411 underlying) - Conversion
Series A2 Preferred Shares
2020-12-15−802,371→ 0 total(indirect: See footnote)→ Common Shares (8,023,710 underlying) - Conversion
Convertible Note
2020-12-15→ 0 total(indirect: See footnote)Exercise: $17.00→ Common Shares (29,411 underlying)
Footnotes (4)
- [F1]These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.
- [F2]The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering ("IPO"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date.
- [F3]The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.
- [F4]This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
Documents
Issuer
AbCellera Biologics Inc.
CIK 0001703057
Entity typeother
Related Parties
1- filerCIK 0001198174
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 8:35 PM ET
- Size
- 18.1 KB